{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"INTerpath-13","nct_id":"NCT07221474","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-13-nct07221474. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"INTerpath-13","arms":[{"description":"Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m\\^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m\\^2 IV infusion weekly × 6 doses). Intismeran Autogene 1 mg intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses.\n\nMaintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Intismeran Autogene 1 mg IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance.","label":"Intismeran Autogene + Pembrolizumab + Chemo","type":"EXPERIMENTAL"},{"description":"Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m\\^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m\\^2 IV infusion weekly × 6 doses). Placebo intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses.\n\nMaintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Placebo IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance.","label":"Placebo + Pembrolizumab + Chemo","type":"EXPERIMENTAL"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2031-05-06","type":"ESTIMATED"},"conditions":["Squamous Non-small Cell Lung Cancer"],"enrollment":{"count":180,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intismeran Autogene","otherNames":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-01","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-07-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to ~32 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to ~42 months"}],"references":[],"start_date":{"date":"2025-12-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","url":"https://clinicaltrials.gov/study/NCT07221474"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-13-nct07221474"}